Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E, Fransen K, Ribas SG, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: florence e. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1664-6. doi: 10.1097/00126334-200412150-00022. J Acquir Immune Defic Syndr. 2004. PMID: 15577426 Free article. Clinical Trial. No abstract available.
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ. Vandekerckhove L, et al. Among authors: florence e. J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31. J Antimicrob Chemother. 2011. PMID: 21196489 Free PMC article.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Gatell JM, et al. Among authors: florence e. AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675. AIDS. 2017. PMID: 29112070 Free PMC article. Clinical Trial.
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium. De Wit S, et al. Among authors: florence e. Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6. Acta Clin Belg. 2018. PMID: 29623779 Free article.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Among authors: florence e. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group. Eron JJ, et al. Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4. Antiviral Res. 2019. PMID: 31279073 Free article. Clinical Trial.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
218 results